Antibodies.com scales operations with huge expansion of Cambridge headquarters
Biological reagent supplier Antibodies.com has made a strategic relocation to Cambridge Technopark, which reflects sustained global growth, with its customer base tripling over five years to serve over 5,000 research institutions worldwide across more than 100 countries.
Life sciences reagent provider Antibodies.com has completed a significant operational expansion, relocating its UK headquarters to a 5,000 square foot facility at Cambridge Technopark – five times larger than its previous premises. The strategic move positions the company at the heart of Cambridge’s established biotechnology cluster whilst addressing substantial capacity constraints driven by sustained global demand growth.
Growth trajectory drives infrastructure investment
The expansion reflects the company’s remarkable growth trajectory over the past five years, during which its customer base has tripled to encompass over 5,000 research institutions globally. The company now maintains a comprehensive catalogue of more than 100,000 products, including primary and secondary antibodies, proteins, and ELISA kits, serving researchers across more than 100 countries.
Enhanced operational capabilities target service delivery
The purpose-built Cambridge Technopark facility features advanced laboratory spaces and modernised logistics infrastructure designed to streamline inventory management and accelerate order fulfilment. Enhanced research and development capabilities are expected to facilitate faster product customisation and reduce turnaround times for customer requirements.
Strategic positioning within biotech ecosystem
The Cambridge location provides direct access to the region’s concentrated life sciences community, complementing Antibodies.com’s existing facilities in Stockholm, Sweden, and St. Louis, US. The headquarters incorporates collaborative workspaces, meeting facilities, and sustainable transport provisions.
Dr Stewart Newlove, CTO and Co-Founder of Antibodies.com, commented: “This move positions us at the centre of the global life sciences community and will enable us to enhance the excellent service our customers have come to expect, scale with global demand, and continued support of innovation in the discovery and development of antibody therapeutics.”
The expansion occurs amid continued growth in antibody therapeutic development, with biological reagents representing critical components in both research and clinical development pipelines. Antibodies.com’s enhanced capacity aims to support accelerated discovery programmes whilst maintaining quality standards across its expanded product portfolio.
Dr Stewart Newlove, CTO and Co-Founder of Antibodies.com
